Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.

Marth, Christian; Alexandre, Jérôme; Hanker, LC; Brown, C.; Kærn, J.; Heywood, M.; Bonaventura, Antonino; Vergote, Ignace; Pignata, Sandro; Ferrero, Annamaria; Gebski, Val; Gropp, M.; Skeie-Jensen, Tone; Giede, Christopher; Vasey, P.; Schauer, Christian; Reed, N.; Ferrandina, G.; Fossati, R.; Pujade-Lauraine, Éric

doi:10.1200/jco.2011.29.15_suppl.5052

Cited by 10 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Global qol scores did not differ between the groups 47 . A 672-patient study, ova-301 48 , compared pld with trabectedin-pld, and found a statistically significantly improved pfs with the combination therapy (7.3 months vs. 5.8 months, p = 0.019).…”

Section: Key Evidence For Recommendationmentioning

confidence: 98%

Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline

et al. 2017

View full text Add to dashboard Cite

Objective The purpose of this guideline is to recommend systemic therapy options for women with recurrent epithelial ovarian cancer, including fallopian tube and primary peritoneal cancers. Methods This document updates the recommendations published in the 2011 Optimal Chemotherapy forRecurrent Ovarian Cancer guideline from Cancer Care Ontario. Draft recommendations were formulated based on evidence obtained through a systematic review of phase ii and iii randomized controlled trials (rcts). The draft recommendations underwent internal review by clinical and methodology experts, and external review by clinical practitioners through a survey assessing the clinical relevance and overall quality of the guideline. Feedback from the internal and external reviews was integrated into the clinical practice guideline. ResultsThe primary literature search yielded thirty-six primary research papers representing thirty rcts that met the eligibility criteria. The guideline provides recommendations for patients with serous tumour histologies and with recurrent, platinum-resistant, and platinum-sensitive ovarian cancer. ConclusionsThe body of evidence from trials that included olaparib and bevacizumab consistently shows a benefit in progression-free survival (pfs) without a corresponding benefit in overall survival (os). The Working Group for this guideline designated pfs, which is associated with symptom control, as a critical outcome. A finding of net benefit can therefore be concluded based on significant differences in pfs. However, that benefit is not without identified harms. Given the identified harms, patient involvement in the decision-making process must take into consideration the side effect profiles of olaparib and bevacizumab within the context of improved pfs but minimal change in os.

show abstract

Section: Key Evidence For Recommendationmentioning

confidence: 98%

Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Platinum-based combinations appear as the most suitable and active treatments for recurrent platinum-sensitive (platinum-free interval >6 months) ovarian cancer patients. Combinations with taxanes [ 29 ], gemcitabine [ 30 ], and pegylated liposomal doxorubicin [ 31 ] reported a median survival of 29, 18, and 31.5 months in the respective superior arms which is generally poorer than the median overall survival reported by the majority of trials of optimally debulked recurrent ovarian cancer patients [ 32 ]. Moreover, a meta-analysis on the role of secondary surgery for recurrent ovarian cancer on 40 studies in 2019 patients reported that each 10% increase in optimally cytoreducted patients translates into a 3-month increase of overall survival [ 33 ].…”

Section: Comparison With Chemotherapymentioning

confidence: 99%

The Role of Secondary Surgery in Recurrent Ovarian Cancer

Lorusso

Mancini

Rocco

et al. 2012

International Journal of Surgical Oncology

View full text Add to dashboard Cite

Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

show abstract

“…Indeed, the improved PFS seen in this study did not translate into an improvement in overall survival. This was not surprising, as the difference in PFS was small and crossover was common [3]. These details make patient-reported outcomes one of the most important metrics in this trial.…”

mentioning

confidence: 91%

Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer

Chase¹,

Wenzel

Monk³

2012

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Most women with ovarian cancer will suffer a recurrence. Unfortunately, although initial treatment can lead to undetectable disease, recurrent disease is often more challenging to control. As curative intent is less common after relapse, patients and doctors argue for improving quality-of-life (QoL) outcomes when therapies are selected. The article reviewed here discusses the QoL results of a trial in platinum-sensitive recurrent ovarian cancer where over 900 patients were randomized to the standard treatment (carboplatin and paclitaxel) versus carboplatin and pegylated liposomal doxorubicin. In the paper under evaluation, the standard of care is challenged based on a favorable clinical outcome in addition to QoL results in the experimental arm.

show abstract

Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): Treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial.

Cited by 10 publications

References 0 publications

Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline

Systemic Therapy for Recurrent Epithelial Ovarian Cancer: A Clinical Practice Guideline

The Role of Secondary Surgery in Recurrent Ovarian Cancer

Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer

Contact Info

Product

Resources

About